Sean Sullivan | Professor
The CHOICE Institute School of Pharmacy

Sean Sullivan, Professor, The CHOICE Institute School of Pharmacy

Sean D. Sullivan, BScPharm, MSc, PhD, is Professor, School of Pharmacy and Visiting Professor (2022-2027), London School of Economics and Political Science. He holds a joint appointment as Professor of Health Services and Population Health, School of Public Health. Dr. Sullivan was Dean of the School of Pharmacy from 2014 to 2022. He completed training in pharmacy at Oregon State University in 1983, obtained a master’s degree at the University of Texas in 1986 and a PhD in health economics and policy at the University of California, Berkeley in 1992. His current research includes topics related to contemporary pharmaceutical policy, medical technology pricing and economic evaluation of medical technology, including pharmaceuticals. He is past president (2003-2004) and treasurer (2020-2026) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and founding chair of the Academy of Managed Care Pharmacy (AMCP) Executive Committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision making. Dr. Sullivan was a member of the Medicare Evidence Development and Coverage Advisory Committee, Chair of the Regence Blue Shield and Premera Blue Cross P/T Committee, and Chair of the Premera Blue Cross Value Assessment Committee. He was awarded the Stephen G. Avey Lifetime Achievement Award (2014) from the Academy of Managed Care Pharmacy (AMCP), and the APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award (2015). In 2020, he was elected to the National Academy of Medicine and in 2022 was elected Fellow, American Association for the Advancement of Science (AAAS). In 2026, he was presented the Avedis Donabedian Lifetime Achievement Award from ISPOR.

Appearances:



Day One @ 10:00

MFN and US Pricing Policy: Preparing for the Upcoming US Legislative Shifts and Their Impact on Global and Long-Term Pricing Strategy

  • The global impact of MFN & International Reference Pricing
  • Future-proofing launch pricing across the US and Europe in the light of US pricing reforms
  • What can the US learn from non-US markets in terms of drug valuation and pricing strategy?  
last published: 08/Sep/26 08:20 GMT

back to speakers

Get Involved 
 

Sponsorship & Exhibition Sales


Steph Scanlon Steph.scanlon@terrapinn.com

 

Speaking Opportunities


Charlie Humphrey
Charlie.humphrey@terrapinn.com
 

Marketing Opportunities


Hidy Lee
hidy.lee@terrapinn.com